Omalizumab

Drugs

Volumn 61, Issue 2, 2001, Pages 253-260

  Easthope, S ^a   Jarvis, B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIBODY PRODUCTION; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; ERYTHEMA; EYE DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; QUALITY OF LIFE; RASH; REVIEW; URTICARIA;

EID: 0035093479     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161020-00008     Document Type: Review

References (29)

1. Allergic rhinobronchitis: The asthma-allergic rhinitis link
2. Treatment of allergic airways disease with anti-IgE
3. Effects of anti-IgE in asthmatic subjects
4. Inhibition of allergic reactions with antibodies to IgE
5. Humanization of an antibody directed against IgE
6. Relationship between the clinical efficacy of rhuMAb-E25 (E25) and serum free IgE in seasonal allergic rhinitis
7. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
8. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis
9. Pharmacokinetics/dynamics following administration of a recombinant humanized monoclonal anti IgE antibody in the cynomolgus monkey
10. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
11. Treatment of allergic asthma with monoclonal anti-IgE antibody, rhuMAb-E25 Study Group
12. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
13. Multiple administrations of the anti-IgE recombinant humanized monoclonal antibody E25 (rhuMAb-E25) reduces free IgE levels in a dose dependent manner in adolescents and children with moderate to severe allergic asthma
14. Down-regulation of human basophil IgE and FCεR[α surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo
15. A pilot study of the effects of an anti-IGE antibody (E25) on airway inflammation in moderatesevere asthma
16. Anti-inflammatory effects of a recombinant monoclonal anti-IgE (E25) in asthma
17. A pharmacodynamic model describing free IgE concentrations following administration of a recombinant humanized monoclonal anti IgE antibody in humans
18. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys
19. The efficacy and safety of rhuMAb-E25 in children with allergic asthma
20. rhuMAb-E25, a novel therapy for the treatment of allergic asthma
21. rhuMAb-E25 improves quality of life in patients with seasonal allergic rhinitis
22. rhuMAb-E25 in the treatment of seasonal allergic rhinitis
23. rhuMAb-E25 improves quality of life in children with allergic asthma
24. rhuMAb-E25, a novel therapy for the treatment of allergic asthma (AA)
25. Recombinant humanized monoclonal antibody (rhuMAb) E25 in the prevention of serious asthma exacerbations
26. rhuMAb-25 (E25) improves asthma-specific quality of life in patients with allergic asthma
27. Safety of readministration of rhuMAb-E25 in seasonal allergic rhinitis